AAV9-mediated heart-failure-inducible PP1βshRNA improved systolic and diastolic function and inhibited LV remodeling.

<p><b>A</b>: Representative M-mode echocardiographic tracings 12 weeks after AAV9-BNP-PP1βshRNA treated MLP knockout mice compared with that of AAV9-BNP-NCshRNA treated mice. <b>B</b>: Serial cardiac function evaluated by echocardiogram after gene transfer. “*” indicates p<0.05 vs the NC group post GT after 12 weeks. “#” indicates p<0.05 vs. an age-matched wild type mouse. <b>C</b>: Representative tracing of LV pressure and dP/dt in the PP1βshRNA and NCshRNA treated groups. The scale bar indicates 200 msec. <b>D</b>: Summaries of the hemodynamic data analysis. “*” indicates p<0.05 vs. the NCshRNA treated group, (n = 7 in the PP1βshRNA treated group, n = 6 in NCshRNA treated group.).